ASXL1 and myelodysplastic syndrome: Although the role of SETBP1 remains unclear, Inoue et al. recently demonstrated that SETBP1 mutations augmented leukemic transformation and subsequently adverse survival in MDS patients with ASXL1 mutations [15].